GlassScriptPhysician profile
Terrence Curley
NPI 1700971058
$8,082.90
in general payments reported to CMS, 2019-2025
37 companies · $806 in 2025
The $806 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,377 · 2020: $915 · 2021: $1,489 · 2022: $1,062 · 2023: $1,437 · 2024: $997 · 2025: $806.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,240.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,239.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,717.60 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $785.91 | 2020-2025 | Jardiance, Tradjenta, Synjardy |
| Lilly USA, LLC | $733.19 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Novo Nordisk INC | $722.37 | 2019-2025 | Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $579.52 | 2019-2025 | Breztri, Airsupra, Fasenra |
| Abbott Laboratories | $423.84 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Merck Sharp & Dohme LLC | $422.02 | 2019-2023 | Verquvo, Belsomra |
| Abbvie INC. | $400.70 | 2019-2025 | Viberzi, Linzess, Vraylar |
| Teva Pharmaceuticals USA, INC. | $319.09 | 2019-2025 | Austedo Xr, Austedo Xr, Ajovy |
| Novartis Pharmaceuticals Corporation | $214.64 | 2019-2024 | |
| Amgen INC. | $158.63 | 2023-2025 | Otezla, Repatha, Otezla |
| Astellas Pharma US INC | $156.76 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $146.87 | 2019-2022 | |
| Pfizer INC. | $120.91 | 2020-2025 | |
| Janssen Pharmaceuticals, INC | $119.72 | 2021-2023 | Xarelto |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $116.51 | 2021-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $111.32 | 2019-2023 | Xifaxan |
| Becton, Dickinson and Company | $77.83 | 2019 | |
| Mannkind Corporation | $72.77 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $64.35 | 2024-2025 | Zoryve |
| Amarin Pharma, INC. | $60.26 | 2019 | |
| Phathom Pharmaceuticals, INC. | $57.36 | 2023-2025 | Voquezna |
| Allergan, INC. | $57.04 | 2019-2020 | |
| Lupin INC. | $50.36 | 2019 | |
| Ucb, INC. | $50.05 | 2024 | Briviact |
| Ironwood Pharmaceuticals, INC | $48.83 | 2020 | |
| Exact Sciences Corporation | $46.86 | 2025 | Cologuard Collection Kit |
| Biogen, INC. | $34.04 | 2020-2021 | |
| Verona Pharma, INC. | $32.08 | 2025 | Ohtuvayre |
| Circassia INC. | $30.27 | 2019 | |
| Smith+Nephew, INC. | $29.60 | 2023 | Collagenase Santyl |
| Vertical Pharmaceuticals, LLC | $27.32 | 2019 | |
| Genzyme Corporation | $23.76 | 2019 | |
| Hikma Pharmaceuticals USA | $22.74 | 2019 | |
| Xeris Pharmaceuticals, INC. | $19.19 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $14.75 | 2021 | |
| Shire North American Group INC | $13.84 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Terrence Curley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.